Biomet announced its earnings before competitors, Stryker and Zimmer, whose stocks rose in value after Biomet’s earnings were released.
Biomet’s saw some decrease in hip and knee sales, with hip sales increasing by 10 percent and knee sales by 9 percent.
Growth in the sector is expected to experience "modest deceleration," according to the report.
Read the Wall Street Journal‘s report on the Biomet quarterly earnings.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.